| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2017 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 1,625 | $40.63 | $66,023.75 | -1.4% | |
| Jan 17, 2017 | NBIX Neurocrine Biosciences Inc | Coughlin Timothy P75 | Chief Financial Officer | Sell | 1,750 | $40.65 | $71,137.50 | -1.3% | |
| Jan 17, 2017 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 15,000 | $38.41 | $576,122.00 | -10.4% | |
| Jan 17, 2017 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 1,625 | $40.65 | $66,056.25 | -2.7% | |
| Jan 17, 2017 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Biodefense Divison | Sell | 8,438 | $29.75 | $251,000.97 | -19.7% | |
| Jan 17, 2017 | EBS Emergent Biosolutions Inc. | Bailey Sue | Director | Sell | 19,424 | $29.78 | $578,425.35 | -8.3% | |
| Jan 17, 2017 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 3,750 | $40.65 | $152,437.50 | -1.5% | |
| Jan 17, 2017 | PCRX Pacira Biosciences, Inc. | Scibetta James S | President | Sell | 20,000 | $38.53 | $770,698.26 | -25.3% | |
| Jan 17, 2017 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 1,625 | $40.63 | $66,023.75 | -1.4% | |
| Jan 17, 2017 | ALKS Alkermes Plc. | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sell | 11,983 | $54.32 | $650,945.32 | -19.1% | |
| Jan 17, 2017 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 1,750 | $40.66 | $71,155.00 | -5.0% | |
| Jan 12, 2017 | IRWD Ironwood Pharmaceuticals Inc | Hecht Peter M | Chief Executive Officer | Sell | 65,987 | $15.67 | $1,034,016.12 | -0.7% | |
| Jan 11, 2017 | SNY Sanofi | Sanofi | 10% Owner | Buy | 87,298 | $369.71 | $32,274,871.70 | - | |
| Jan 10, 2017 | EBS Emergent Biosolutions Inc. | Abdun-Nabi Daniel | President And CEO | Sell | 28,240 | $31.28 | $883,296.37 | -13.0% | |
| Jan 9, 2017 | ALKS Alkermes Plc. | Stejbach Mark | Svp/ Chief Comm Off, Alks Inc | Sell | 547 | $60.27 | $32,967.69 | -1.6% | |
| Jan 9, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 550 | $60.27 | $33,148.50 | -0.9% | |
| Jan 6, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 9,450 | $60.06 | $567,548.03 | -4.7% | |
| Jan 6, 2017 | ALKS Alkermes Plc. | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sell | 10,000 | $59.44 | $594,425.33 | -4.5% | |
| Jan 6, 2017 | ALKS Alkermes Plc. | Stejbach Mark | Svp/ Chief Comm Off, Alks Inc | Sell | 9,453 | $60.05 | $567,686.53 | -8.5% | |
| Jan 4, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 65,114 | $85.16 | $5,545,108.24 | -1.7% | |
| Jan 4, 2017 | ALKS Alkermes Plc. | Breyer Robert A | Director | Sell | 4,000 | $60.00 | $240,000.00 | -26.4% | |
| Jan 4, 2017 | PAHC Phibro Animal Health Corp | Dagger Thomas G | SVP, GC And Corp Secretary | Sell | 207 | $30.00 | $6,210.00 | -100% | |
| Jan 3, 2017 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 1,980 | $10.46 | $20,711.00 | -7.2% | |
| Jan 3, 2017 | ALKS Alkermes Plc. | Gaffin David Joseph | SVP, CLO, Alkermes, Inc. | Sell | 2,500 | $55.40 | $138,500.00 | -9.1% | |
| Jan 3, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 400 | $18.61 | $7,444.00 | -0.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.